• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Deutsche Bank initiated coverage on ACADIA Pharmaceuticals with a new price target

    2/11/25 7:00:07 AM ET
    $ACAD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACAD alert in real time by email
    Deutsche Bank initiated coverage of ACADIA Pharmaceuticals with a rating of Hold and set a new price target of $22.00
    Get the next $ACAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACAD

    DatePrice TargetRatingAnalyst
    5/21/2025$35.00Hold → Buy
    Deutsche Bank
    2/11/2025$22.00Hold
    Deutsche Bank
    1/3/2025$23.00 → $20.00Buy → Neutral
    Guggenheim
    10/10/2024Mkt Perform
    Raymond James
    8/7/2024$28.00 → $20.00Overweight → Equal-Weight
    Morgan Stanley
    6/27/2024$31.00Outperform
    BMO Capital Markets
    3/12/2024$36.00 → $32.00Buy
    Needham
    3/12/2024$39.00 → $25.00Buy → Neutral
    Mizuho
    More analyst ratings

    $ACAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Brege Laura sold $314,634 worth of shares (14,446 units at $21.78), decreasing direct ownership by 49% to 15,095 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      6/5/25 6:01:14 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Daly James M converted options into 9,387 shares, increasing direct ownership by 38% to 34,041 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      6/2/25 6:05:06 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ndu Adora converted options into 9,387 shares, increasing direct ownership by 61% to 24,801 units (SEC Form 4)

      4 - ACADIA PHARMACEUTICALS INC (0001070494) (Issuer)

      6/2/25 6:05:12 PM ET
      $ACAD
      Biotechnology: Pharmaceutical Preparations
      Health Care